COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,235 Articles (22,733 medRxiv, 8,502 bioRxiv)

Most recent first Previous |  Page 2232: Articles 22311-22320  | Next

Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease
Dolan, M. E., Hill, D. P., Mukherjee, G., McAndrews, M. S., Chesler, E. J., Blake, J. A.
10.1101/2020.09.21.306720 — Posted: 2020-09-21
Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19
Ma, J., Su, D., Huang, X., Liang, Y., Ma, Y., Liang, P., Zheng, S.
10.1101/2020.09.21.306357 — Posted: 2020-09-21
Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry
Ren, W., Hu, G., Zhao, X., Wang, Y., Shi, H., Lan, J., Zhu, Y., Wu, J., Kenney, D. J., Florian, D., Tong, Y., Zhong, J., Xie, Y., Wang, X., Yuan, Z., Zhou, D., Zhang, R., Ding, Q.
10.1101/2020.09.20.297242 — Posted: 2020-09-21
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
Wu, N. C., Yuan, M., Bangaru, S., Huang, D., Zhu, X., Lee, C.-C. D., Turner, H. L., Peng, L., Yang, L., Nemazee, D., Ward, A. B., Wilson, I. A.
10.1101/2020.09.21.305441 — Posted: 2020-09-21 Discussion: Onsite | Offsite
Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor
Taka, E., Yilmaz, S. Z., Golcuk, M., Kilinc, C., Aktas, U., Yildiz, A., Gur, M.
10.1101/2020.09.21.305490 — Posted: 2020-09-21
Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection
Graham, J., Swarts, J., Leist, S. R., Schafer, A., Menachery, V. D., Gralinski, L., Jeng, S., Miller, D. R., Mooney, M., McWeeney, S., Ferris, M. T., Pardo-Manuel de Villena, F., Heise, M. T., Baric, R. S., Lund, J. M.
10.1101/2020.09.21.306837 — Posted: 2020-09-21
Rapid detection of inter-clade recombination in SARS-CoV-2 with Bolotie
Varabyou, A., Pockrandt, C., Salzberg, S. L., Pertea, M.
10.1101/2020.09.21.300913 — Posted: 2020-09-21
Common genetic variation in humans impacts in vitro susceptibility to SARS-CoV-2 infection
Dobrindt, K., Hoagland, D. A., Seah, C., Kassim, B., O'Shea, C., Iskhakova, M., Fernando, M., Deans, P. M., Powell, S., Javidfar, B., Murphy, A., Peter, C., Moeller, R., Fernandez Garcia, M., Kimura, M., Iwasawa, K., Crary, J., Kotton, D., Takebe, T., Huckins, L., tenOever, B., Akbarian, S., Brennand, K. J.
10.1101/2020.09.20.300574 — Posted: 2020-09-21
COMPARATIVE ANALYSIS OF COVID-19 MORTALITY IN BRAZIL, RIO DE JANEIRO, CAMPOS DOS GOYTACAZES, MACAE, CABO FRIO AND RIO DAS OSTRAS
C. Guimaraes, A. C., Santa Cruz Coelho, K., da Cruz, K. T., Soares de Oliveira Souza, B., Forastieri de Almeida, J., Fialho Coelho, G., Ramos Lacerda Ferreira, G.
10.1101/2020.09.17.20196444 — Posted: 2020-09-21
Comparison of COVID-19 outcomes among shielded and non-shielded populations: A general population cohort study of 1.3 million
Jani, B. D., Ho, F. K., Lowe, D. J., MacBride-Stewart, S., Mair, F. S., Pell, J. P.
10.1101/2020.09.17.20196436 — Posted: 2020-09-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).